Episode 13: The Missing Middle: Life Sciences Real Estate's Smallest TenantsEpisode descriptionStates love to recruit the marquee win — the mega-plant, the ribbon cutting. But the company that actually seeds a life sciences cluster ten years from now rarely looks like that. It's small, pre-revenue, and scientifically brilliant people who have no idea how to read a lease. This episode follows that gap — the "missing middle" of life sciences real estate — through three vantage points: a brokerage building a resource to keep early-stage biotech tenants from getting stuck in bad leases, a university tech-transfer office building the infrastructure to catch companies before they fail, and a 100-year-old pharmaceutical company that's already on the other side of it, breaking ground on a $2 billion biologics facility built to last generations. GuestsDavid Klein, Managing Partner, Lee & Associates (San Francisco)Elijah Hodges, Life Sciences Team, Lee & AssociatesKathy Nugent, Director, Institute for Innovation and Entrepreneurship, University of Alabama at Birmingham (UAB)Ray Watts, President, University of Alabama at BirminghamPhilippe Mantelet, Head of Global Engineering, Sites and Facilities, UCB In this episodeSegment 1 — The lease nobody prepared them for. David Klein and Elijah Hodges of Lee & Associates built LabSpace Directory, a free resource for early-stage biotech tenants navigating their first lab lease. Klein describes the two failure modes that wreck young life sciences companies: under-programming space and getting trapped renegotiating with a landlord who holds all the leverage, or over-leasing and getting saddled with dark space the company can't afford. Hodges explains why founders — deep experts in their own science — routinely skip the real estate, architecture, and space-planning professionals who could keep them out of trouble. Segment 2 — Building the infrastructure to catch them. At UAB, Kathy Nugent and President Ray Watts describe an institution built almost entirely around life sciences: 93% of UAB's research funding comes from NIH, and 95% of the companies it has spun out in the last five years are biotech. Nugent details UAB's approach to the gap between discovery and company — recruiting CEOs who don't relocate to Birmingham but keep the company's footprint there, and building Station 41, an 11,000-square-foot wet lab incubator (expanding to 30,000) a block from campus. Alabama's Innovate Alabama tax credit program funnels contract research funding — up to $400,000–$500,000 per company — to help early-stage tenants there access preclinical services. Segment 3 — The other side of the gap. Philippe Mentolea of UCB, the Belgian family-owned pharmaceutical company, discusses the $2 billion biologics manufacturing facility UCB is building in Gwinnett County, Georgia — a project meant to anchor its U.S. manufacturing supply chain for decades. Mentolea explains what won Georgia the project (a 30-year relationship, site readiness, and shared long-term vision), why none of the competing sites "failed" so much as one edged ahead on fit, and the advice he'd give other site selectors: don't chase short-term incentives on a project built to last a generation. Notable lines"It's scientists who are brilliant at biology and chemistry that have no idea how to read a lease." — David Klein"I don't know. You tell me." / "I can't tell you. You have to tell me." — Klein, on CEOs who haven't programmed their space needs"I hate using the word valley of death... but it's pretty steep right now." — Kathy Nugent"Failing or failure is not an option, and there is no blocking point." — Philippe Mentolea CreditsHosted by Andy Greiner, editor, Area Development magazine. A production of Area Development / Halcyon Business Publications. Mentioned in this episode: This episode is sponsored by TNECD